Pagina 1 a partire dal 38 risultati
CROSS REFERENCE TO RELATED APPLICATIONS
This application is the U.S. National Phase of International Application No. PCT/ES2014/070463, filed Jun. 5, 2014, designating the U.S. and published in Spanish as WO 2014/195553 on Dec. 11, 2014 which claims the benefit of Spain Patent Application No.
BACKGROUND OF THE INVENTION
The field of the invention is treating post-seizure patients to interfere with epileptogenesis.
The highest incidence of seizures during lifetime is found in the neonatal period and neonatal seizures lead to a propensity for epilepsy and long-term cognitive deficits. Here
BACKGROUND OF THE INVNON
1. Field of the Invention
The present invention is directed to aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds. In particular, this invention is directed to aryl-link-aryl thiazohdine-ione, and aryl-link-aryl oxazolidine-dione compounds which
BACKGROUND
Status epilepticus is a condition in which the brain is in a state of persistent seizure. There is evidence that 30-60 minutes of persistent seizure is sufficient to damage neurons and that such a seizure is unlikely to self-terminate. Status epilepticus survivors may die soon after or
BACKGROUND
Status epilepticus is a condition in which the brain is in a state of persistent seizure. There is evidence that 30-60 minutes of persistent seizure is sufficient to damage neurons and such a seizure is unlikely to self-terminate. Status epilepticus survivors may die soon after or have
BACKGROUND
Status epilepticus is a condition in which the brain is in a state of persistent seizure. There is evidence that 30-60 minutes of persistent seizure is sufficient to damage neurons and such a seizure is unlikely to self-terminate. Status epilepticus survivors may die soon after or have
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates in general to the field of transdermal and dermal drug delivery by using formulations of said compositions including chemical penetrants molecules, polar solvents, cream base, antioxidants and therapeutic
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to new N-(5-aminomethyl-2-oxazolin-2-yl)-N'-phenylureas, the method for producing them and their therapeutic application.
2. Description of the Prior Art
2-Amino-2-oxazolines are already known. Thus,
TECHNICAL FIELD
The present invention is useful in medical fields. In more detail, novel imidazoline compounds of this invention are useful as neuropeptide Y receptor antagonists and as agents for the treatment of various kinds of cardiovascular disorders, central nervous system disorders, metabolic
This application is a 371 of PCT/JP01/01312 filed Feb. 22, 2001.
TECHNICAL FIELD
The present invention is useful in medical fields. In more detail, novel imidazoline compounds of this invention are useful as neuropeptide Y receptor antagonists and as agents for the treatment of various kinds of
1. FIELD OF THE INVENTION
The present invention relates to Cyanoiminopiperazine Compounds, compositions comprising an effective amount of a Cyanoiminopiperazine Compound and methods for treating or preventing pain, urinary incontinence (UI), an ulcer, inflammatory-bowel disease (IBD),
1. FIELD OF THE INVENTION
The present invention relates to Cyanoiminopiperazine Compounds, compositions comprising an effective amount of a Cyanoiminopiperazine Compound and methods for treating or preventing pain, urinary incontinence (UI), an ulcer, inflammatory-bowel disease (IBD),
1. FIELD OF THE INVENTION
The present invention relates to 3-substituted Pyridyl Compounds, compositions comprising an effective amount of a 3-substituted Pyridyl Compound and methods for treating or preventing a condition such as pain comprising administering to an animal in need thereof an
1. FIELD OF THE INVENTION
The present invention relates to 3-substituted Pyridyl Compounds, compositions comprising an effective amount of a 3-substituted Pyridyl Compound and methods for treating or preventing a condition such as pain comprising administering to an animal in need thereof an
TECHNICAL FIELD
The present disclosure relates to certain heterocycle fused morphianans. Compounds of the present disclosure are mixed mu agonist delta antagonists or dual mu agonist/delta agonists or antagonists at mu, delta and kappa opioid receptors. Compounds of the present disclosure are useful